Figure 1.
Light chain kinetics outcomes in the first cycle of daratumumab-based therapy. (A) The median time to sFLC reduction ≥50% was 3 days (95% CI, 3-7). (B) The median time to sFLC reduction ≤500 mg/L was 14.5 days (95% CI, 9-49).
Light chain kinetics outcomes in the first cycle of daratumumab-based therapy. (A) The median time to sFLC reduction ≥50% was 3 days (95% CI, 3-7). (B) The median time to sFLC reduction ≤500 mg/L was 14.5 days (95% CI, 9-49).
